To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 1 / Phase 2	2026-05-18		NCT04661007

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Incyte Biosciences Japan GK	2

23 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Aichi Cancer Center Hospital	Aichi	Japan	2
Chiba Cancer Center	Chiba	Japan	27
IUHW Narita Hospital	Narita	Japan	5
Japanese Red Cross Nagoya Daini Hospital	Nagoya	Japan	2
Kanagawa Cancer Center	Yokohama	Japan	17
Kindai University Hospital	Sayama	Japan	2
Kobe City Medical Center General Hospital	Hyōgo	Japan	7
Kyushu University Hospital	Fukuoka	Japan	20
Mie University Hospital	Tsu	Japan	2
National Cancer Center Hospital	Tokyo	Japan	42
National Cancer Center Hospital East	Chiba	Japan	25
National Hospital Organization Kyushu Cancer Center	Fukuoka	Japan	46
Nho Disaster Medical Center	Tachikawa	Japan	1
Nho Hokkaido Cancer Center	Sapporo	Japan	3
Nho Kumamoto Medical Center	Kumamoto-ken	Japan	1
NHO Okayama Medical Center	Okayama	Japan	2
NHO Shikoku Cancer Center	Matsuyama	Japan	5
Osaka University Hospital	Suita-shi	Japan	6
Saitama Medical Center	Saitama-shi	Japan	1
The Cancer Institute Hospital of Jfcr	Kōtoku	Japan	19
Tohoku University Hospital	Miyagi	Japan	16
Tokai University Hospital	Kanagawa	Japan	13
University of Fukui Hospital	Fukui	Japan	4

Clinical trials